sars sonrası 4 ders - rım...ergönül.pdf · pdf filekırım kongo kanamalı...
TRANSCRIPT
![Page 1: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/1.jpg)
Kırım Kongo Kanamalı Ateşi
Tedavi
Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul
![Page 2: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/2.jpg)
Sunum İçeriği
• Epidemiyoloji güncelleme
• Patogenez
• Tedavi
• Korunma
![Page 3: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/3.jpg)
Kırım Kongo Kanamalı Ateşi Risk ve Olgu Haritası
![Page 4: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/4.jpg)
![Page 5: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/5.jpg)
Türkiye’de Kırım Kongo Kanamalı Ateşi
![Page 6: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/6.jpg)
Karesh WB, Lancet 2012
![Page 7: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/7.jpg)
Crimean-Congo Hemorrhagic Fever
Ergonul O, In Emerging Infections, 2014, Elsevier
![Page 8: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/8.jpg)
Rural area: 70% of the cases
Male/female ratio: 1.13/1
Tick bite history among patients: 69%
May, June, July: 84% of the cases
Epidemiologic characteristics
Yilmaz GR, et al. The Epid. of CCHF in Turkey in 2002-2007. Int J Infect Dis 2008
![Page 9: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/9.jpg)
Clinical Features
![Page 10: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/10.jpg)
Ergonul O, Lancet ID, 2006
![Page 11: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/11.jpg)
Fatality Among Hospitalized Children
33 children in İran: 24% (Sharifi-Mood, et al. Ped Infect Dis J 2008)
31 children in Turkey: 0% (Tezer H, et al. J Clin Virol 2010)
50 children in Turkey; 0% (Tuygun N, et al. Pediatr Int 2011)
0
100
00
02
00
00
03
00
00
0
Pla
tele
t co
un
t
0 5 10 15Age by years
![Page 12: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/12.jpg)
Gestation (weeks) Ig M Ig G PZR Outcome
1. Mother 38 + + - Survived
Baby C/S + + Fatal
2. Mother 19 + + Survived
Baby vaginal(Term) - - NEC
Fatal
3. Mother 28 + + Fatal
Baby Fatal
Pregnancy and CCHF
Ergönül Ö, et al. CMI 2009
![Page 13: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/13.jpg)
Feldmann and Geisbert, Lancet 2011
![Page 14: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/14.jpg)
07.03.2016 Crimean-Congo Hemorrhagic Fever Analysis
https://mehmetgonen.shinyapps.io/crimean_congo_hemorrhagic_fever_analysis/ 3/27
Cytokine Levels of Controls versus Patients
Ergonul, et al. 2016
![Page 15: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/15.jpg)
07.03.2016 Crimean-Congo Hemorrhagic Fever Analysis
https://mehmetgonen.shinyapps.io/crimean_congo_hemorrhagic_fever_analysis/ 25/27
Cytokine Levels of Different Severity Groups forFirst Five Days
Ergonul, et al. 2016
![Page 16: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/16.jpg)
The goal of the therapy is the prevention of fatality
![Page 17: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/17.jpg)
Hematologic support
Fluid and electrolyte balance should be sustained
If necessary;
Blood,
Trombocyte suspension,
Fresh frozen plasma
![Page 18: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/18.jpg)
Supportive Therapy
• What are the standards of supportive therapy?
• Preventive measures in patient care
![Page 19: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/19.jpg)
010
20
30
0 1
Ta
ze
do
nm
us p
lazm
a (
un
ite
)
Graphs by EX
Fresh frozen plasma
p=0.002
010
20
30
40
0 1
Tro
mb
osit (
un
ite
)
Graphs by EX
Thrombocyte suspension
p=0.001
Ergonul, et al. CMI 2006
Confounding by indication
Survived cases fatal cases Survived cases fatal cases
![Page 20: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/20.jpg)
Arenaviridae
Lassa Fever
South America HF
Bunyaviridae
Hanta
Rift Valley
CCHF
Ribavirin: A Broad Spectrum Antiviral Only Drug for VHFs
![Page 21: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/21.jpg)
Inspirations from EBV and other HFs
favipiravir brinsidofovir ZMapp TKM-Ebola “antisense” oligonükleotidler (PMOs) BCX4430
![Page 22: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/22.jpg)
![Page 23: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/23.jpg)
![Page 24: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/24.jpg)
Ostereich L, et al. Plos One, 2014
![Page 25: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/25.jpg)
Ribavirin is effective in vitro
Effective in vitro
Watts DM, et al. Am J Trop Med Hyg 1989
Inhibits viremia among rats
Tignor GH, et al. Antiviral Res 1993
The most effective among the alternatives
Paragas J, et al. Antiviral Res 2004
![Page 26: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/26.jpg)
Author, year Cases Fatality in ribavirin group
Fatality in no ribavirin group
Fisher-Hoch 1995
3 SÇ 0/3 (0%) -
Mardani 2003
69 42/139 (30%) 22/48 (46%)
Ergonul 2006
45
0/22 (0) 1/23 (4.3%)
Ozkurt 2006
26 2/22 (9%) 4/38 (10.5%)
Elaldı, 2009 218 126 (7.1%) 92 (11.9%)
Clinical Observations: Case series, historical control
![Page 27: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/27.jpg)
The Role of Observational Studies
Goldberger believed that an infectious disease
was unlikely to distinguish between inmates
and employees or so systematically between
rich and poor, and he favoured the hypothesis
that a superior diet protected people from
pellagra. He had also in mind the case of beri-
beri, a disease which had recently been shown
to be responsive to dietary interventions.
(Vandenbroucke 2003).
![Page 28: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/28.jpg)
Problems in Study Design: What We Learned?
A. Study Design
1.Inclusion criteria 1. Severity
2. Confounding by indication
2.Number of days from onset of symptoms
1. Prehemorhagic
2. Hemorhagic 1. Ineffective application:
GIS symptoms in oral use (hematemesis)
3. Duration of treatment
B. Statistical Analysis
1.P value is not everything; sample size is important
2.Meta-analysis: oranges & apples; early vs late
![Page 29: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/29.jpg)
Clin Infect Dis 2013
Clin Infect Dis 2004
![Page 30: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/30.jpg)
Clin Infect Dis 2013
![Page 31: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/31.jpg)
PLTs
Incubation
3-7 days
Prehemorrhagic period 1-7 days
Hemorrhagic
period 2-3 days
Convelescence
AST and ALT
Fatality
7 d 10 d days
Disseminated
Intravascular Coagulation
viremia
EARLY PHASE
LATE PHASE
Ribavirin could be more effective in early phase
CYTOKINES
Ergonul O. Treatment of CCHF, Antivir Res 2008
The Role of Ribavirin in CCHF
![Page 32: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/32.jpg)
J Med Ethics 2011
![Page 33: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/33.jpg)
If the physicians who are against the use of ribavirin were to be infected
with the CCHF virus (which I sincerely hope never occurs), would they
reject ribavirin treatment?
Galen: primum non nocere.
So, why not give this treatment to the patients?
![Page 34: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/34.jpg)
![Page 35: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/35.jpg)
CCHF studies with comparison groups
Early use
Ribavirin No ribavirin
Overall
Ribavirin No Ribavirin
![Page 36: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/36.jpg)
Favours
Ribavirin
Favours
No Ribavirin
Ozturk and Ergonul, Klimik 2011 (abst)
![Page 37: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/37.jpg)
Favours
Early
Ribavirin
Favours
Late
Ribavirin
Ozturk and Ergonul, Klimik 2011 (abst)
Early Use is More Effective
![Page 38: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/38.jpg)
No difference in fatality
![Page 39: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/39.jpg)
VHF Human to human transmission
Ebola High
Marburg High
Lassa Moderate
S.America Low
Hantaan No
RV No
CCCF High
Yellow fever No
Dengue No
Omsk Not reported
Kyasanur Not reported
Alkhumra Not reported
![Page 40: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/40.jpg)
![Page 41: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/41.jpg)
Index case
50, male, FATAL
Physician
47, m, FATAL
Wife
47, m, survived
Brother
42, m, FATAL
39 contacts
27 HCWs
Nosocomial Infection in Tajikistan, 2009
Ergonul O, et al. WHO report, 2009
![Page 42: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/42.jpg)
Mardani, et al. Am J Trop Med 2009
Transmission of CCHF to HCWs
3 out of 5 (60%) died
No ribavirin use 10 years ago in Iran
![Page 43: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/43.jpg)
What precautions should be used for HCW ?
http://www.mkk.de/cms/media/bilder/presse/2002/50/Lassa.jpg
![Page 44: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/44.jpg)
Hand hygiene and use of PPE based on risk assessment
• Always before and after patient contact, and after contact with contaminated environmental surfaces or equipment
• If direct contact with patient’s blood and body fluids, secretions, excretions, mucous membranes or non-intact skin
• If there is a risk of spills onto the health-care worker’s face
![Page 45: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/45.jpg)
![Page 46: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/46.jpg)
![Page 47: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/47.jpg)
IJID, 2015
![Page 48: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/48.jpg)
![Page 49: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/49.jpg)
Emerg Infect Dis 2014
![Page 50: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/50.jpg)
Emerg Infect Dis 2014
![Page 51: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/51.jpg)
Ribavirin in Post-Exposure Prophylaxis for Lassa Fever
The authors recommend oral ribavirin postexposure prophylaxis for Lassa fever exclusively for definitive high-risk exposures.
Bausch DG, et al. Review of the literature and proposed guidelines for the use of oral ribavirin as
postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010
![Page 52: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/52.jpg)
Ergonul, in press
![Page 53: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/53.jpg)
Ergonul, in press
![Page 54: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/54.jpg)
High risk exposure
n=146
PEP Ribavirin
n=56 (38%)
Infected
n=7 (12.5%)
symptomatic
n=6 (86%)
Fatal
n=0 (0%)
Not infected
n=49 (87.5%)
no PEP
n=90 (62%)
Infected
n=87 (97%)
symptomatic
n=86 (99%)
Ribavirin <48 hrs after
symptoms
n=12
Fatal
n=0 (0%)
No ribavirin <48 hours after
symptoms
n=74
Fatal
n=32 (43%)
Not infected
n=3 (3%)
Ergonul, in press
![Page 55: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/55.jpg)
Exposure
Risk assessment
Low risk
Follow up with CBC
Normal Results in 14 days
Stop follow up
Low WBC and PLT
isolation
supportive tx
Tx with Ribavirin
High risk
PEP with ribavirin
watchfull care
Ergonul, in press
![Page 56: SARS sonrası 4 ders - rım...ERGÖNÜL.pdf · PDF fileKırım Kongo Kanamalı Ateşi Tedavi Onder Ergonul, MD, MPH Koç Universitesi, Tıp Fakültesi, Istanbul 6 Ekim 2016, Istanbul](https://reader031.vdocuments.pub/reader031/viewer/2022020214/5a78cbf17f8b9a4f1b8c6910/html5/thumbnails/56.jpg)
Birlikte Çalışmalarımız için Teşekkürler
Dr. Başak Dokuzoğuz Dr. Aysel Çelikbaş Dr. Şebnem Eren Dr. Nurcan Baykam Dr. Barış Öztürk Dr. Ayşe Erbay Dr. Nuriye Fışgın Dr. Saliha Özbey Dr. Ayşen Gargılı Dr. Zati Vatansever Dr. Sırrı Kır
Dr. Mehmet Gönen Dr. Füsun Can Dr. Çiğdem Ak Dr. Kenan Midilli